DXCM - DexCom, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
129.00
-3.85 (-2.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close132.85
Open136.00
Bid124.00 x 800
Ask136.92 x 800
Day's Range128.71 - 136.57
52 Week Range43.74 - 148.56
Volume990,086
Avg. Volume1,171,070
Market Cap11.398B
Beta (3Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-0.06
Earnings DateNov 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est142.75
Trade prices are not sourced from all markets
  • Most Analysts Are Bullish on Tandem Stock
    Market Realist3 days ago

    Most Analysts Are Bullish on Tandem Stock

    Seven of the total ten analysts covering Tandem Diabetes Care (TNDM) in October 2018 have given Tandem a “buy” or higher rating, and three analysts have given Tandem a “hold” rating. The mean rating for Tandem is 2.1 with a target price of $52.5, which implies an upside potential of 36.7% over Tandem’s trading price of $38.40 on October 17.

  • DexCom Launches CLARITY Mobile App, Strengthens CGM Profile
    Zacks4 days ago

    DexCom Launches CLARITY Mobile App, Strengthens CGM Profile

    DexCom (DXCM) benefits from the diabetes care space as it adopts cloud-based services for Continuous Glucose Monitoring.

  • What Can We Expect from Tandem’s Bottom Line in Third Quarter?
    Market Realist4 days ago

    What Can We Expect from Tandem’s Bottom Line in Third Quarter?

    Tandem Diabetes Care (TNDM) is expected to incur a net loss of $18.22 million in the third quarter of 2018. Its net loss was $16.03 million in the year-ago period, which translates into a net loss per share of $0.33 for the third quarter of fiscal 2018 as compared with a net loss per share of $3.09 for the third quarter of fiscal 2017. On October 12, Tandem announced that its t:slim X2 insulin pump received approval in Canada and is the only continuous glucose monitoring (or CGM) integrated insulin pump approved in the country.

  • Business Wire4 days ago

    Dexcom G6® Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries with Diabetes in Early 2019

    DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today the new Dexcom G6® CGM System will be covered for Medicare beneficiaries, having met the category requirements for therapeutic CGM systems by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage for therapeutic CGM includes certain beneficiaries who have either Type 1 or Type 2 diabetes and intensively manage their insulin.

  • Could JNJ’s Medical Device Business Report Strong Growth in Q3?
    Market Realist10 days ago

    Could JNJ’s Medical Device Business Report Strong Growth in Q3?

    Johnson & Johnson’s (JNJ) Medical Device business has posted steadily improving performance in recent quarters. Since then, Johnson & Johnson has efficiently implemented a restructuring plan for its Medical Device business, which resulted in significant growth in the segment’s performance. In the second quarter, Johnson & Johnson’s Medical Device business reported sales of ~$7.0 billion, which contributed 33.5% to the company’s total sales of $20.8 billion.

  • PR Newswire11 days ago

    Dexcom Announces Release of Clarity Mobile App

    EDINBURGH , October 11, 2018 /PRNewswire/ -- Mobile app allows patients to quickly access glucose data on their phone for diabetes management   Dexcom , Inc. (NASDAQ:DXCM), a leader in continuous glucose ...

  • The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
    Zacks13 days ago

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

    The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    Dexcom Inc NASDAQ/NGS:DXCM

  • Wearable Medical Device Boom Puts These 3 Stocks in Focus
    Zacks14 days ago

    Wearable Medical Device Boom Puts These 3 Stocks in Focus

    Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.

  • Business Wire14 days ago

    DexCom Schedules Third Quarter 2018 Earnings Release and Conference Call for November 6, 2018 at 4:30 p.m. Eastern Time.

    DexCom, Inc. today announced that it plans to release its third quarter 2018 financial results after market close on Tuesday, November 6, 2018. Management will hold a conference call to review the company's third quarter 2018 performance starting at 4:30 p.m.

  • US Diabetes Market Gaining Momentum: 3 Stocks in Focus
    Zacks18 days ago

    US Diabetes Market Gaining Momentum: 3 Stocks in Focus

    A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.

  • Investing in Diabetes Stocks: A Beginner's Guide
    Motley Fool24 days ago

    Investing in Diabetes Stocks: A Beginner's Guide

    Want to put money to work in this $825 billion market? Here's what you need to know.

  • DexCom Inc (NASDAQ:DXCM): Are Analysts Optimistic?
    Simply Wall St.last month

    DexCom Inc (NASDAQ:DXCM): Are Analysts Optimistic?

    DexCom Inc’s (NASDAQ:DXCM): DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The US$12.64bRead More...

  • 10 Boring Stocks Growing Like Weeds
    InvestorPlacelast month

    10 Boring Stocks Growing Like Weeds

    Most investors love a good story — or should I say, a sexy story. In looking for stocks to buy, they like the stories of the companies that are transforming an entire industry or are exploiting a niche that no one even knew existed 20 minutes ago. It’s the rags-to-riches tale, the ground-floor-stock temptation.

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Dexcom Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 10. Index (PMI) data, output in the Healthcare sector is rising.

  • DexCom Has Reported 150% Growth in 2018 Year-to-Date
    Market Realistlast month

    DexCom Has Reported 150% Growth in 2018 Year-to-Date

    The stock of DexCom (DXCM), the leading pure-play diabetes medtech player, has risen ~150%, from $57.99 on January 2, 2018, to $143.48 on September 7, 2018. In the second quarter, it reported revenues of $242.5 million, a YoY (year-over-year) rise of 42.1%. It reported a 35% YoY rise in revenues for the US market, while sales outside the United States rose 78% YoY in Q2 2018.

  • Why DexCom Soared 51.8% in August
    Motley Fool2 months ago

    Why DexCom Soared 51.8% in August

    Growing demand in the wake of next-generation diabetes devices sparked optimism.

  • Here's Why You Should Hold On to DexCom (DXCM) Stock Now
    Zacks2 months ago

    Here's Why You Should Hold On to DexCom (DXCM) Stock Now

    DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...

  • Business Wire2 months ago

    Dexcom Acquires TypeZero Technologies

    DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies, Inc. (“TypeZero”). TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery. Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery (“AID”) and smart pens.

  • Business Wire2 months ago

    DexCom Announces Upcoming Conference Presentation

    DexCom, Inc. today announced that management will present an update on DexCom at the following upcoming investor conference:

  • See what the IHS Markit Score report has to say about Dexcom Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Dexcom Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DXCM earnings conference call or presentation 1-Aug-18 8:30pm GMT

    Q2 2018 DexCom Inc Earnings Call

  • Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring
    Bloomberg2 months ago

    Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring

    Diabetes treatment has evolved since Mary Fortune was diagnosed in 1967 and hospitalized because there was no reliable way monitor her blood sugar. Fortune and other diabetics are benefiting from an explosion in technology and innovation, from under-the-skin sensors that eliminate the need for painful finger pricks, to smartphone alerts when glucose levels rise too high. For glucose monitors alone, the number of published patent applications has grown steadily for a decade and has accelerated significantly since 2015, according to an analysis by the research firm Patinformatics.